Evidence map›Paper›PMID 40238764›Full record

ArticlePloS one2025

Effective polyclonal antibodies against the virulence-associated protein D (VapD) of Helicobacter pylori, obtained from recombinant VapD.

Alejandro Flores-Alanis, Gabriela Delgado, Carlos Santiago-Olivares, Víctor Manuel Luna-Pineda, Armando Cruz-Rangel, Denilson Guerrero-Mejía, María Luisa Escobar-Sánchez, Nayeli Torres-Ramírez, Rosario Morales-Espinosa

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Expression of the VapD protein byMicrobiology (Reading, England) · 2026
    Article
  2. Microorganisms · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alejandro Flores-AlanisDepartamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Gabriela DelgadoDepartamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Carlos Santiago-OlivaresDepartamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Víctor Manuel Luna-PinedaLaboratorio de Investigación en Patógenos Respiratorios y Producción de Biológicos, Hospital Infantil de México "Federico Gómez", Mexico City, Mexico.ORCID 0000-0002-3078-9423
Armando Cruz-RangelLaboratorio de Bioquímica de Enfermedades Crónicas, Instituto Nacional de Medicina Genómica, Mexico City, Mexico.
Denilson Guerrero-MejíaLaboratorio de Inmunobiología y Diagnóstico Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Guerrero, Guerrero, Mexico.
María Luisa Escobar-SánchezDepartamento de Biología Celular, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Nayeli Torres-RamírezDepartamento de Biología Celular, Facultad de Ciencias, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Rosario Morales-EspinosaDepartamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico.ORCID 0000-0003-2110-4397

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Helicobacter pylori is a microorganism associated with serious gastric pathologies. This bacterium presents specific genes that encode for different virulence factors associated with the development of gastric disease. The VapD protein has rarely been studied, although it has been previously demonstrated its participation in the protection of Helicobacter pylori within gastric cells. In the present work, we document the protocols developed to generate the VapD recombinant protein and the subsequent production of polyclonal antibodies. Our research group faced several problems throughout the trials; however, all of them were successfully solved.

Indexed as

Antibodies, BacterialBacterial ProteinsHelicobacter pyloriVirulence FactorsAnimalsHumansMiceRecombinant ProteinsAntibodies, BacterialBacterial ProteinsRecombinant ProteinsVirulence Factors

Identifiers

PMID40238764
PMCPMC12002528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.